title: The influence of Bone Morphogenic Protein-2 on the consolidation phase in a distraction osteogenesis model.
abstract: We asked whether locally applied recombinant-Bone Morphogenic Protein-2 (rh-BMP-2) with an absorbable Type I collagen sponge (ACS) carrier could enhance the consolidation phase in a callotasis model. We performed unilateral transverse osteotomy of the tibia in 21 immature male rabbits. After a latency period of 7 days, a 3-weeks distraction was begun at a rate of 0.5mm/12h. At the end of the distraction period (Day 28) animals were randomly divided into three groups and underwent a second surgical procedure: 6 rabbits in Group I (Control group; the callus was exposed and nothing was added), 6 rabbits in Group II (ACS group; receiving the absorbable collagen sponge soaked with saline) and 9 rabbits in Group III (rh-BMP-2/ACS group; receiving the ACS soaked with 100μg/kg of rh-BMP-2, Inductos(®), Medtronic). Starting at Day 28 we assessed quantitative and qualitative radiographic parameters as well as densitometric parameters every two weeks (Days 28, 42, 56, 70 and 84). Animals were sacrificed after 8 weeks of consolidation (Day 84). Qualitative radiographic evaluation revealed hypertrophic calluses in the Group III animals. The rh-BMP-2/ACS also influenced the development of the cortex of the calluses as shown by the modified radiographic patterns in Group III when compared to Groups I and II. Densitometric analysis revealed the bone mineral content (BMC) was significantly higher in the rh-BMP-2/ACS treated animals (Group III).
authors: Department of Animal Experimental Surgery, National Veterinary School of Maison Alfort, France.
authors: Valérie
authors: V
authors: Lesaichot
authors: Dimitri
authors: D
authors: Leperlier
authors: Véronique
authors: V
authors: Viateau
authors: Delphine
authors: D
authors: Richarme
authors: Hervé
authors: H
authors: Petite
authors: Frédéric
authors: F
authors: Sailhan
mesh_terms: D020341:Absorbable Implants; D000704:Analysis of Variance; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D002146:Bony Callus / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000502:physiology; D024042:Collagen Type I; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008297:Male; D019857:Osteogenesis, Distraction; D010027:Osteotomy; D011817:Rabbits; D011859:Radiography; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013977:Tibia / Q000000981:diagnostic imaging / Q000601:surgery*; D013997:Time Factors
chemical_list: D055396:Bone Morphogenetic Protein 2; D024042:Collagen Type I; D011994:Recombinant Proteins